Lyell Immunopharma, Inc. Common Stock
Symbol: LYEL (NASDAQ)
0.00
▼ (-100.00%) -13.070
Company Description:
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Key Stats
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $13.07
- Yesterday High: $13.5
- Yesterday Low: $12.89
- Yesterday Volume: 24.69K
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
Company Profile
- Name: Lyell Immunopharma, Inc. Common Stock
- Website: https://www.lyell.com
- Listed Date: 2021-06-17
- Location: SOUTH SAN FRANCISCO, CA
- Market Status: Active
- CIK Number: 0001806952
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $251.09M
- Round Lot: 100
- Outstanding Shares: 19.21M
- Asset Type: CS
RECENT FILINGS FOR LYEL
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-22 | 4 | View |
| 2025-08-22 | 4 | View |
| 2025-08-22 | 4 | View |
| 2025-08-22 | 4 | View |
| 2025-08-19 | SCHEDULE 13G | View |
| 2025-08-15 | EFFECT | View |
| 2025-08-13 | 4 | View |
| 2025-08-13 | 4 | View |
| 2025-08-13 | 4 | View |
| 2025-08-13 | 4 | View |
| 2025-08-12 | S-3 | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-08-01 | SCHEDULE 13G | View |
| 2025-07-31 | 424B5 | View |
| 2025-07-30 | EFFECT | View |
| 2025-07-29 | 4 | View |
| 2025-07-29 | 3 | View |
| 2025-07-28 | CORRESP | View |
| 2025-07-25 | 8-K | View |
Latest News on LYEL